Objective To analyze the application value of Ningbitai capsules combined with surgery in the treatment of chronic prostatitis (CP) with benign prostatic hyperplasia (BPH). Methods The clinical data of 76 patients with CP complicated with BPH admitted to Liaocheng Third People's Hospital from June 2019 to June 2022 were retrospectively collected, and they were divided into two groups according to different treatment methods, with 38 cases in each group. The observation group was (61.58±6.44) years old, and the control group was (62.31±7.28) years old. All patients underwent transurethral plasmakinetic resection of prostate (PKRP). The control group was given routine treatment, and the observation group was given Ningbitai capsules on the basis of the control group. The medication started 2 weeks before surgery and continued till 2 weeks after surgery, for a total of 1 month.The operation-related indexes, levels of inflammatory markers [macrophage inflammatory protein-1α (MIP-1α), vascular cell adhesion molecule-1 (VCAM-1), and interleukin-6 (IL-6)] before treatment, 1 d before surgery, and 2 weeks after surgery, and urodynamic indexes [maximum urinary flow rate (Qmax), residual urine volume (PVR), and bladder stability], National Institutes of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) scores, and International Prostatitis Symptom Scale (IPSS) scores before treatment, 1 day before surgery, and 3 months after surgery were compared between the two groups. Independent sample t test and paired t test were used. Results The operation time, hospital stay, and intraoperative blood loss were (51.49±12.44) min, (5.19±0.98) days, and (79.58±8.13) ml in the observation group, and (68.73±14.35) min, (6.08±1.22) days, (98.55±10.24) ml in the control group, respectively, with statistically significant differences (t=5.596, 3.506, and 8.944, all P<0.01). Serum MIP-1α, VCAM-1, and IL-6 levels in the observation group were (14.95±2.18) µg/L, (72.58±8.51) ng/L, and (185.73±32.62) ng/L 1 day before surgery, those were (6.51±1.38) µg/L, (40.28±8.75) ng/L, and (119.24±35.58) ng/L 2 weeks after surgery, and the results in the control group were (16.83±2.27) µg/L, (81.44±8.22) ng/L, and (215.37±31.11) ng/L 1 day before surgery and (8.11±1.44) µg/L, (54.56±7.93) ng/L, and (153.15±39.48) ng/L 2 weeks after surgery, with statistically significant differences (t=3.682, 4.616, 4.053, 4.945, 7.454, and 3.993, all P<0.001). The Qmax, bladder stability, and PVR in the observation group 3 months after surgery were (12.39±2.47) ml/s, (174.65±15.32) ml, and (44.66±15.26) ml, those in the control group were (9.25±2.31) ml/s, (154.51±16.83) ml, and (62.79±14.93) ml, with statistically significant differences (t=5.724, 5.455, and 5.235, all P<0.001). The NIH-CPSI score of the observation group was (17.17±2.11) 1 day before surgery and (7.84±1.08) points 3 months after surgery, while those of the control group were (19.16±2.15) and (10.29±1.25) points (t=4.072 and 9.143, both P<0.001). The IPSS score of the observation group was lower than that of the control group 3 months after surgery [(8.17±1.43) points vs. (11.22±1.68) points] (t=8.552, P<0.001). Conclusion Ningbitai capsules combined with PKRP in the treatment of CP with BPH can reduce the inflammatory reaction, improve the urodynamics, and helps to recover.